{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:04:08Z","timestamp":1761807848283,"version":"build-2065373602"},"reference-count":69,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T00:00:00Z","timestamp":1381795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p>Almost half of the pregnancies in the <jats:styled-content style=\"fixed-case\">U<\/jats:styled-content>nited <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>tates are unintended. Currently available contraceptive methods are highly efficacious, but the most commonly used methods rely on patients for appropriate use. There has been a push to advocate for long\u2010acting reversible contraceptives (<jats:styled-content style=\"fixed-case\">LARC<\/jats:styled-content>s) as first\u2010line methods because they are placed by medical professionals and are the most effective form of reversible contraception available. There are four <jats:styled-content style=\"fixed-case\">LARC<\/jats:styled-content>s currently available in the <jats:styled-content style=\"fixed-case\">United States<\/jats:styled-content>: the Copper T intrauterine device, two forms of the levonorgestrel intrauterine system, and the etonogestrel subdermal implant. Once inserted, they can be left in place for 3\u201310\u00a0years, depending on the device. Some of these devices have been available for a number of years, but their use is limited in the <jats:styled-content style=\"fixed-case\">United States<\/jats:styled-content> due to controversies and misconceptions. A <jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content> search from 1990\u20132012 was conducted to identify articles describing the use of <jats:styled-content style=\"fixed-case\">LARC<\/jats:styled-content>s in populations with limited data, including postpartum women, adolescents and nulliparous women, and women with sexually transmitted infections, including human immunodeficiency virus (<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>). Health care provider safety concerns surrounding intrauterine device (<jats:styled-content style=\"fixed-case\">IUD<\/jats:styled-content>) expulsions and infection are issues for use in adolescents and nulliparous women. Concern regarding <jats:styled-content style=\"fixed-case\">IUD<\/jats:styled-content> expulsion in the postpartum population questions the benefit of immediate versus delayed insertion, and the progestin effect in the levonorgestrel <jats:styled-content style=\"fixed-case\">IUD<\/jats:styled-content> and etonogestrel implant is of theoretic concern for breastfeeding women. In women with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>, concerns have been raised about increased viral shedding with the <jats:styled-content style=\"fixed-case\">IUD<\/jats:styled-content> and drug interactions with the progestin methods. Many misconceptions surrounding <jats:styled-content style=\"fixed-case\">LARC<\/jats:styled-content>s are unfounded, but individual risk factors may leave <jats:styled-content style=\"fixed-case\">LARC<\/jats:styled-content> users at risk of unintended pregnancy if not addressed properly.<\/jats:p>","DOI":"10.1002\/phar.1358","type":"journal-article","created":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T12:19:54Z","timestamp":1381839594000},"page":"46-59","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long\u2010Acting Reversible Contraception: A Review in Special Populations"],"prefix":"10.1002","volume":"34","author":[{"given":"Gina M.","family":"Prescott","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice University at Buffalo School of Pharmacy and Pharmaceutical Sciences Buffalo New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University at Buffalo School of Pharmacy and Pharmaceutical Sciences Buffalo New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.07.016"},{"key":"e_1_2_12_3_1","first-page":"26","article-title":"Current contraceptive use in the United States, 2006\u20102010, and changes in patterns of use since 1995","volume":"60","author":"Jones J","year":"2012","journal-title":"National Health Statistics Reports"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.07.013"},{"key":"e_1_2_12_5_1","unstructured":"U.S. Department of Health and Human Services.Office of Disease Prevention and Health Promotion. Healthy People 2020. Available fromhttp:\/\/www.healthypeople.gov\/2020\/topicsobjectives2020\/objectiveslist.aspx?topicId=13. Accessed September 20 2012."},{"key":"e_1_2_12_6_1","unstructured":"Health Resources and Services Administration.Women's preventive services: required heath plan coverage guidelines Available fromhttp:\/\/www.hrsa.gov\/womensguidelines\/. Accessed March 27 2013."},{"volume-title":"Contraceptive technology: Twentieth Revised Edition","year":"2011","author":"Hatcher RA","key":"e_1_2_12_7_1"},{"key":"e_1_2_12_8_1","first-page":"184","article-title":"ACOG Practice Bulletin No. 121: long\u2010acting reversible contraception: implants and intrauterine devices","volume":"1","author":"American College of Obsterticians and Gynecologists","year":"2011","journal-title":"Obstet Gynecol"},{"volume-title":"Managing contraception on the go","year":"2012","author":"Zieman M","key":"e_1_2_12_9_1"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"115 e1","DOI":"10.1016\/j.ajog.2010.04.017","article-title":"The Contraceptive CHOICE Project: reducing barriers to long\u2010acting reversible contraception","volume":"2","author":"Secura GM","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_12_11_1","unstructured":"U.S. medical eligibility criteria for contraceptive use 2010.MMWR Recomm Rep2010;RR\u20104:1\u201386."},{"volume-title":"Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone","year":"2010","author":"World Health Organization","key":"e_1_2_12_12_1"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.04.005"},{"key":"e_1_2_12_14_1","unstructured":"Teva Women's Health Inc.ParaGard T 380A intrauterine copper contraceptive package insert.Sellersville PA:Teva Pharmaceuticals USA Inc."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.01.021"},{"key":"e_1_2_12_16_1","unstructured":"RED BOOK Online. Available fromhttp:\/\/www.micromedexsolutions.com. Accessed May 20 2013."},{"key":"e_1_2_12_17_1","unstructured":"U.S. Food and Drug Administration.FDA approves additional use for IUD Mirena to treat heavy menstrual bleeding in IUD users. Available fromhttp:\/\/www.fda.gov\/News Events\/Newsroom\/PressAnnouncements\/ucm184747.htm. Accessed October 13 2009."},{"key":"e_1_2_12_18_1","unstructured":"Washington University School of Medicine.Levonorgestrel Intrauterine System for Emergency Contraception (LIFE). In:ClinicalTrials.gov.Bethesda MD:National Library of Medicine. Available fromhttp:\/\/clinicaltrials.gov\/show\/NCT01539720NLM Identifier: NCT01539720. Accessed March 29 2013."},{"key":"e_1_2_12_19_1","unstructured":"Bayer HealthCare Pharmaceuticals Inc.Mirena (levenorgestrel\u2010releasing intrauterine system) package insert.Wayne NJ:Bayer HealthCare Pharmaceuticals Inc. 2009."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(90)90046-X"},{"key":"e_1_2_12_21_1","unstructured":"Bayer HealthCare Pharmaceuticals Inc.SKYLA (levonorgestrel\u2010releasing intrauterine system) package insert.Wayne NJ:Bayer HealthCare Pharmaceuticals Inc. 2013."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.12.003"},{"key":"e_1_2_12_23_1","unstructured":"Merck & Co. Inc.Nexplanon (etonogestrel subdermal implant) package insert.Whitehouse Station NJ:Merck & Co. Inc. 2012."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318259565a"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318273eb56","article-title":"Preventing unintended pregnancies by providing no\u2010cost contraception","volume":"6","author":"Peipert JF","year":"2012","journal-title":"Obstet Gynecol"},{"key":"e_1_2_12_26_1","first-page":"1","article-title":"Birth rates for U.S. teenagers reach historic lows for all age and ethnic groups","volume":"89","author":"Hamilton BE","year":"2012","journal-title":"NCHS Data Brief"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110855"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31821188ad"},{"key":"e_1_2_12_29_1","first-page":"878","article-title":"Medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period","volume":"26","author":"Centers for Disease Control and Prevention. Update to CDC's U.S","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_12_30_1","first-page":"1S","article-title":"Breastfeeding: maternal and infant aspects. Special report from ACOG","volume":"1","author":"American College of Obsterticians and Gynecologists","year":"2007","journal-title":"ACOG Clin Rev"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.03.024"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(83)90013-6"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9378(82)90679-2","article-title":"Copper intrauterine contraceptive device event rates following insertion 4 to 8\u00a0weeks post partum","volume":"1","author":"Mishell DR","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.11.019"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181f73fac"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2007.06.003"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2003.12.004"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.01.022"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.04.004"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.05.124"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(00)00173-6"},{"key":"e_1_2_12_42_1","first-page":"983","article-title":"Committee opinion no. 539: adolescents long\u2010acting reversible contraception: implants intrauterine devices","volume":"4","author":"American College of Obstetricians and Gynecologists","year":"2012","journal-title":"Obstet Gynecol"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","unstructured":"SchelarE FranzettaK ManloveJ.Repeat teen childbearing: differences across states by race and ethnicity. Child Trends Research Brief2007.","DOI":"10.1037\/e407272008-001"},{"key":"e_1_2_12_44_1","first-page":"1","article-title":"Abortion surveillance\u2013United States, 2009","volume":"8","author":"Pazol K","year":"2012","journal-title":"MMWR Surveil Summ"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.03.001"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2010.07.005"},{"key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/AOG.0b013e31827499bd","article-title":"Continuation of reversible contraception in teenagers and young women","volume":"6","author":"Rosenstock JR","year":"2012","journal-title":"Obstet Gynecol"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2012.01.005"},{"key":"e_1_2_12_49_1","unstructured":"Office of Population Affairs.Title X family planning. Available fromhttp:\/\/www.hhs.gov\/opa\/title-x-family-planning\/. Accessed May 21 2013."},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.03.014"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.12.006"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02699-4"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.08.007"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91904-M"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853899309164163"},{"key":"e_1_2_12_56_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/AOG.0b013e318273364c","article-title":"Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease","volume":"6","author":"Sufrin CB","year":"2012","journal-title":"Obstet Gynecol"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.10.004"},{"key":"e_1_2_12_58_1","unstructured":"Centers for Disease Control and Prevention.Estimated HIV incidence in the United States 2007\u20132010. HIV surveillance supplemental report 2012 2012;No. 4."},{"key":"e_1_2_12_59_1","first-page":"449","article-title":"Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV","volume":"24","author":"Centers for Disease Control and Prevention. Update to CDC's U.S","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_12_60_1","first-page":"1492","article-title":"ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus","volume":"6","author":"American College of Obsterticians and Gynecologists","year":"2010","journal-title":"Obstet Gynecol"},{"key":"e_1_2_12_61_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents.2013. \u201cElectronic Article\u201d"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318269c8bb"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000363778.58203.b6"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/del264"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.09.006"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.09.002"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.09.005"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118907782101724"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2009.009469"},{"key":"e_1_2_12_70_1","unstructured":"Bristol\u2010Meyers Squibb Company.Sustiva (efavirenz oral capsule tablets) package insert.Princeton NJ:Bristol\u2010Meyers Squibb Company 2013."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1358","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:33:40Z","timestamp":1761042820000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1002\/phar.1358"],"URL":"https:\/\/doi.org\/10.1002\/phar.1358","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2013,10,15]]},"assertion":[{"value":"2013-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}